BPC-157
WellnessWeight Management
In plain English
BPC-157 is a synthetic peptide, based on a sequence found in stomach fluid, that is widely promoted for healing tendons, muscles, and the gut. In animal studies it appears to speed tissue repair and reduce inflammation. However, high-quality human evidence is essentially absent—only a few small pilot studies exist—so its benefits in people are not proven. It is not FDA-approved, and in 2023 the FDA restricted its use in compounding.
The science
BPC-157 is a stable pentadecapeptide reported in numerous rodent models to accelerate healing of tendon, ligament, muscle, and gastrointestinal tissue. Proposed mechanisms include promotion of angiogenesis (upregulating VEGFR2 via the nitric-oxide pathway), enhanced fibroblast migration/survival (FAK-paxillin signaling), and anti-inflammatory effects (Chang et al., 2011; Gwyer et al., 2019). Crucially, human clinical evidence is extremely limited—only a handful of small pilot studies—and no adequately powered randomized trials support its use (as emphasized in a 2025 narrative review). It is not FDA-approved; the FDA placed BPC-157 in a category that restricts pharmacy compounding. It is frequently compounded with thymosin beta-4 and KPV.
References
- Chang CH et al., J Appl Physiol 2011 (preclinical, tendon)
- Gwyer D et al., Cell Tissue Res 2019 (preclinical review)
- Seed A et al., Curr Rev Musculoskelet Med 2025 (narrative review; human data extremely limited)